title: Long-term outcomes and patient satisfaction of continent catheterizable limb and augmentation cystoplasty simultaneous with salvage prostatectomy.
abstract: OBJECTIVE
  We evaluated the long-term outcomes of augmentation cystoplasty and continent catheterizable limb formation in patients who underwent simultaneous salvage prostatectomy.
  
  
  METHODS
  Twelve men who underwent salvage prostatectomy with augmentation cystoplasty and either an appendicovesicostomy or Monti ileovesicostomy between October 2000 and February 2003 were assessed for long-term surgical complications, reoperations, continence rates, and patient satisfaction using the Incontinence Symptom Index (ISI) questionnaire and a self-designed catheterization questionnaire.
  
  
  RESULTS
  In addition to bladder augmentation, six patients underwent appendicovesicostomy, four had a Monti ileovesicostomy and two a spiral Monti ileovesicostomy. There were no intraoperative complications or surgical-related deaths. Four patients required revision surgery (33%) at a mean of 39 months. Minor revisions were performed for stomal stenosis in two patients with stomal relocation in two patients. Ten of 12 patients were dry (83.3%) with a catheterization frequency of between 3 and 8 hr. At a mean follow-up of 61 months (SD = 20.51), the mean ISI severity score was 1.86 (SD = 3.54) and the mean ISI bother score was 1 (SD 0.74). The majority (86%) would choose to undergo the surgery again.
  
  
  CONCLUSIONS
  Although surgically challenging and associated with significant morbidity, salvage prostatectomy with concomitant bladder augmentation and continent catheterizable reconstruction is a feasible and effective means of obtaining adequate long-term urinary continence, while preserving the native bladder. In comparison to similar historical patients with catheterizable limbs only, fewer of the augmented patients needed antimuscarinic medication and delayed augmentation was not necessary. Complications do not increase over time and the continence rates are stable.
authors.affiliation: MD Anderson Cancer Center, University of Texas, Houston, Texas 77030, USA.
authors.forename: Helen
authors.initials: H
authors.lastname: Zafirakis
authors.forename: Elise J B
authors.initials: EJ
authors.lastname: De
authors.forename: Louis L
authors.initials: LL
authors.lastname: Pisters
authors.forename: Curtis
authors.initials: C
authors.lastname: Pettaway
authors.forename: O Lenaine
authors.initials: OL
authors.lastname: Westney
mesh_terms: D000368:Aged; D003559:Cystostomy / Q000009:adverse effects; D005834:Genital Neoplasms, Male / Q000473:pathology / Q000503:physiopathology / Q000532:radiotherapy / Q000601:surgery*; D006801:Humans; D007081:Ileostomy / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000627:therapeutic use; D009364:Neoplasm Recurrence, Local; D017060:Patient Satisfaction; D011468:Prostatectomy / Q000009:adverse effects; D012086:Reoperation; D016879:Salvage Therapy; D011795:Surveys and Questionnaires; D013997:Time Factors; D016896:Treatment Outcome; D014546:Urinary Catheterization; D014549:Urinary Incontinence / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D014563:Urodynamics
chemical_list: D018727:Muscarinic Antagonists